替加环素及其他8种抗菌药物对经分子方法鉴定的不同诺卡菌属菌种的体外活性。
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
作者信息
Cercenado Emilia, Marín Mercedes, Sánchez-Martínez Mónica, Cuevas Oscar, Martínez-Alarcón José, Bouza Emilio
机构信息
Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Dr. Esquerdo 46, 28007 Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2007 Mar;51(3):1102-4. doi: 10.1128/AAC.01102-06. Epub 2006 Dec 28.
Abstract
The in vitro activities of tigecycline and other antimicrobials against 51 isolates of Nocardia spp. were evaluated. MIC(90)s and MIC ranges were as follows: tigecycline, 4 and < or =0.06 to 8 mg/liter, respectively; minocycline, 2 and < or =0.06 to 2 mg/liter, respectively; linezolid, 1 and < or =0.06 to 2 mg/liter, respectively; moxifloxacin, 2 and < or =0.06 to >64 mg/liter, respectively; ertapenem, 32 and < or =0.06->64 mg/liter, respectively; imipenem, 2 and < or =0.06 to >64 mg/liter, respectively; meropenem, 8 and < or =0.06 to >64 mg/liter, respectively; amikacin, 1 and < or =0.06 to 32 mg/liter, respectively; and trimethoprim-sulfamethoxazole, 1/19 and < or =0.5/9.5 to >2/38 mg/liter, respectively.
摘要
评估了替加环素和其他抗菌药物对51株诺卡菌属菌株的体外活性。MIC（90）和MIC范围如下：替加环素分别为4以及≤0.06至8毫克/升；米诺环素分别为2以及≤0.06至2毫克/升；利奈唑胺分别为1以及≤0.06至2毫克/升；莫西沙星分别为2以及≤0.06至＞64毫克/升；厄他培南分别为32以及≤0.06至＞64毫克/升；亚胺培南分别为2以及≤0.06至＞64毫克/升；美罗培南分别为8以及≤0.06至＞64毫克/升；阿米卡星分别为1以及≤0.06至32毫克/升；以及复方磺胺甲恶唑分别为1/19以及≤0.5/9.5至＞2/38毫克/升。
相似文献
1
In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods.
Antimicrob Agents Chemother. 2007 Mar;51(3):1102-4. doi: 10.1128/AAC.01102-06. Epub 2006 Dec 28.
2
Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.
J Antimicrob Chemother. 2009 Jul;64(1):73-8. doi: 10.1093/jac/dkp144. Epub 2009 Apr 27.
3
In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2007 May;51(5):1621-6. doi: 10.1128/AAC.01099-06. Epub 2007 Feb 16.
4
In vitro activity of tigecycline and 10 other antimicrobials against clinical isolates of the genus Corynebacterium.
Int J Antimicrob Agents. 2009 May;33(5):453-5. doi: 10.1016/j.ijantimicag.2008.11.001. Epub 2009 Jan 18.
5
Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
Diagn Microbiol Infect Dis. 2008 Sep;62(1):67-80. doi: 10.1016/j.diagmicrobio.2008.04.012. Epub 2008 May 29.
6
Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.
Antimicrob Agents Chemother. 2004 Nov;48(11):4479-81. doi: 10.1128/AAC.48.11.4479-4481.2004.
7
Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.
Antimicrob Agents Chemother. 2011 May;55(5):2084-91. doi: 10.1128/AAC.01808-10. Epub 2011 Feb 22.
8
In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
Int J Antimicrob Agents. 2008 Nov;32 Suppl 3:S188-91. doi: 10.1016/S0924-8579(08)70026-8.
9
In vitro activity of tigecycline against Bacteroides species.
J Antimicrob Chemother. 2005 Aug;56(2):349-52. doi: 10.1093/jac/dki197. Epub 2005 Jun 10.
10
Determination of antimicrobial susceptibility patterns of Nocardia spp. from clinical specimens by Etest.
Clin Microbiol Infect. 2006 Sep;12(9):905-12. doi: 10.1111/j.1469-0691.2006.01460.x.
引用本文的文献
1
Invasive Pulmonary Aspergillosis and Nocardia Pneumonia in a Pediatric Patient With Chronic Lung Disease: A Case Report.
Case Rep Pediatr. 2025 Jul 17;2025:6659641. doi: 10.1155/crpe/6659641. eCollection 2025.
2
A rare case of multiple brain abscesses caused by Nocardia abscessus co-infection with tuberculous meningitis in an immunocompetent patient.
BMC Infect Dis. 2025 May 13;25(1):694. doi: 10.1186/s12879-025-11056-5.
3
Overlapping infections of and in an immunocompetent patient: A case report.
World J Clin Cases. 2024 Apr 26;12(12):2079-2085. doi: 10.12998/wjcc.v12.i12.2079.
4
Clinical characteristics and drug resistance of Nocardia in Henan, China, 2017-2023.
Ann Clin Microbiol Antimicrob. 2024 Mar 6;23(1):23. doi: 10.1186/s12941-024-00677-4.
5
Cerebral Abscess Due to Nocardia beijingensis Associated With HIV: Case Report and Mini Review.
Cureus. 2023 Oct 24;15(10):e47571. doi: 10.7759/cureus.47571. eCollection 2023 Oct.
6
Pulmonary and central nervous system nocardiosis: Alcoholism as an immunocompromising factor.
Biomedica. 2023 Mar 30;43(1):37-43. doi: 10.7705/biomedica.6606.
7
Nocardia caishijiensis infection: a case report and review of the literature.
BMC Infect Dis. 2023 Apr 6;23(1):218. doi: 10.1186/s12879-023-08186-z.
8
Surfactant nanovesicles for augmented antibacterial activity against carbapenemase resistant enterobacteriaceae and extended spectrum beta-lactamases producing bacteria: in vitro and in vivo evaluation.
BMC Microbiol. 2023 Mar 16;23(1):73. doi: 10.1186/s12866-023-02812-1.
9
A Rare Case of Co-Infection with , , and Due to Tooth Extraction in a Mildly Immunosuppressed Patient.
Infect Drug Resist. 2022 Aug 25;15:4853-4857. doi: 10.2147/IDR.S379005. eCollection 2022.
10
Multiple Brain Abscesses Caused by Nocardia Beijingensis in a Patient With HIV Infection.
Cureus. 2022 Jun 8;14(6):e25754. doi: 10.7759/cureus.25754. eCollection 2022 Jun.
本文引用的文献
1
Determination of antimicrobial susceptibility patterns of Nocardia spp. from clinical specimens by Etest.
Clin Microbiol Infect. 2006 Sep;12(9):905-12. doi: 10.1111/j.1469-0691.2006.01460.x.
2
Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy.
Clin Microbiol Rev. 2006 Apr;19(2):259-82. doi: 10.1128/CMR.19.2.259-282.2006.
3
Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.
Antimicrob Agents Chemother. 2005 Sep;49(9):3903-9. doi: 10.1128/AAC.49.9.3903-3909.2005.
4
Sequence-based identification of aerobic actinomycetes.
J Clin Microbiol. 2004 Jun;42(6):2530-40. doi: 10.1128/JCM.42.6.2530-2540.2004.
5
In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis.
Antimicrob Agents Chemother. 2004 Mar;48(3):832-7. doi: 10.1128/AAC.48.3.832-837.2004.
6
In vitro activities of new antimicrobials against Nocardia brasiliensis.
Antimicrob Agents Chemother. 2004 Feb;48(2):602-4. doi: 10.1128/AAC.48.2.602-604.2004.
7
Nocardiosis: review of clinical and laboratory experience.
J Clin Microbiol. 2003 Oct;41(10):4497-501. doi: 10.1128/JCM.41.10.4497-4501.2003.
8
Oxazolidinone antibiotics.
Lancet. 2001 Dec 8;358(9297):1975-82. doi: 10.1016/S0140-6736(01)06964-1.
9
Evaluation of E test, disk diffusion and broth microdilution to establish tentative quality control limits and review susceptibility breakpoints for two aerobic actinomycetes.
Diagn Microbiol Infect Dis. 2001 Aug;40(4):179-86. doi: 10.1016/s0732-8893(01)00273-5.
10
Linezolid: an oxazolidinone antimicrobial agent.
Clin Ther. 2001 Mar;23(3):356-91. doi: 10.1016/s0149-2918(01)80043-6.
Zotero 插件